Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
Date:8/5/2009

ue 75 -- 75 -- TOTAL REVENUE 18,364 389 21,694 588 OPERATING EXPENSES: Cost of services -- 14 -- 14 Research and development: Non-cash compensation 361 251 562 (729) Other research and development 1,456 4,242 2,830 35,069 Total research and development 1,817 4,493 3,392 34,340 Selling, general and administrative: Non-cash compensation 1,028 1,767 1,398 3,484 Other selling, general and administrative 1,528 2,078 2,569 3,965 Total selling, general and administrative 2,556 3,845 3,967 7,449 TOTAL OPERATING EXPENSES 4,373 8,352 7,359 41,803 OPERATING INCOME (LOSS) 13,991 (7,963) 14,335 (41,215) OTHER INCOME (EXPENSE): Interest and other income (expense), net 141 274 248 (929) INCOME (LOSS) FROM CONTINUING OPERATIONS 14,132 (7,689) 14,583 (42,144) Loss from discontinued operations -- (8) -- (89) NET INCOME (LOSS) $ 14,132 $ (7,697) $ 14,583 $ (42,233) NET INCOME (LOSS)PER COMMON SHARE Basic $ 0.30 $ (0.17) $ 0.30 $ (0.96) Diluted $ 0.29 $ (0.17) $ 0.30 $ (0.96) SHARES USED IN COMPUTING NET LOSS PER COMMON SHARE Basic 47,855,425 44,095,873 47,854,664 43,906,974 Diluted 48,189,552 44,095,873 48,149,600 43,906,974 Balance Sheet Information: June 30,
'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...honored by latest award for revolutionary hearing ... November 16, 2009 -- Popular Science Magazine has...id from InSound Medical a winner of its coveted Be...y.    Chosen from thousands of... hearing canal for up to four months while providi...
(Date:11/18/2009)...ble to find explosive materials and persons who ha..., the National Institute of Standards and Technolo...eland Security, has developed a new certified refe...2905, Trace Particulate Explosives. Compatible wit... be helpful in calibrating, testing and developing...
(Date:11/18/2009)... data analysis combined with Bio-Rad,s Biotech...icula provide state-of-the-art solutions to biotec... Vernier Software & Technology...nsors, and software and Bio-Rad Laboratories, Inc....life science research and clinical diagnostics pro...
(Date:11/18/2009)...RNewswire-FirstCall/ - YM BioSciences Inc. (NYSE A...lopment company that identifies and advances a div...s at various stages of development, announced that...presented today in a poster at the 2009 AACR-NCI-E...ference in Boston, Massachusetts. The reported res...
Breaking Biology Technology:Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3New NIST trace explosives standard slated for homeland security duty 2Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3
...enosumab is a new drug being,studied to prevent fr...al,therapy. Results of a phase 3 clinical trial us... San Antonio Breast Cancer Symposium by Georgiana,... Denosumab is a highly specific antibody that int...zed cells that break down bone. Because it is,high...
...ontinuing Interest in Peregrine,s Anti-PS Technolo... -, TUSTIN, Calif., Dec. 14 Peregrine,Pharmaceut...pharmaceutical,company developing monoclonal antib...virus (HCV) infection, today announced the sudden ...ract award with the Defense Threat,Reduction Agenc...
...l Potential Uses, Excluding U.S. and Japan, No Ot...ase BASINGSTOKE, England and PHILADELPHIA, Decemb...Q),the global specialty biopharmaceutical company,...e rights, excluding the U.S. and Japan, to AT-1001...1 is Alba,s lead inhibitor,of barrier dysfunction ...
Other Biology Technology:New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment 2Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program 2Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program 3Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program 4Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation 2Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation 3
(Date:11/20/2009)... CHAMPAIGN, Ill. In a new study, researchers rep...blockers can have a helpful, or harmful, effect on... , The study, which appears in the journal Circ...arget both the alpha- and beta-receptors on the he...nts, while those that target only the beta-recepto...
(Date:11/19/2009)... MADISON Leaf-cutter ants, which cultivate fungu...ere,s a new one to add to the list: the ant farmer...en-fixing bacteria to make their gardens grow. The...nal Science , documents a previously unknown symb...ht into how leaf-cutter ants have come to dominate...
(Date:11/19/2009)... When it comes to corn, 1 + 1 = more than 2: The ...r to both of their parents. Characterizing the gen... known as heterosis or hybrid vigor, could boost o...its, such as high protein content for human consum..., With help from the newly released DNA sequence ...
Breaking Biology News(10 mins):Carvedilol shown to have unique characteristics among beta blockers 2Like humans, ants use bacteria to make their gardens grow 2U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2Scientists Find New Key to Lupus 59752 1Scientists Find New Key to Lupus 59752 2Majesco Entertainment and Interactive Game Group Release Jillian Michaels Fitness Ultimatum 2010 For Nintendo DS 28TM 29 59747 1Majesco Entertainment and Interactive Game Group Release Jillian Michaels Fitness Ultimatum 2010 For Nintendo DS 28TM 29 59747 2Majesco Entertainment and Interactive Game Group Release Jillian Michaels Fitness Ultimatum 2010 For Nintendo DS 28TM 29 59747 3Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 1Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 2Blue Cross and Blue Shield of Florida Now Offers More Choices to Floridas Seniors 59742 3
...ay provide a less-invasive alternative for diabeti...lood to keep glucose levels in check. The common m...lucose testing strips and metres can be painful, i...ineers at the Schulich School of Engineering at th...led the Electronic Mosquito. The patch is approxim...
...ght have a good side. Wild mice from a Nottinghams...f Nottingham clues as to the importance of some pa...natural" immune system. , Jan Bradley, Professor ...lian immunology is largely based on rodents reared...onditions. Analysing the immune response in wild p...
.... announced that the results from its United State...cteron will be presented today at the 44th Annual ...of the Liver (EASL) in Copenhagen, Denmark. Locter...igned to improve patient care by providing a more ... by reducing the side effects, including flu-like ...
Other Biology News:Blood testing, mosquito style 2Lice can be nice to us 2Biolex presents Locteron US Phase 2a hepatitis C data at EASL 2Biolex presents Locteron US Phase 2a hepatitis C data at EASL 3
Cassette, Xba I from Takara Mirus Bio
Cassette, EcoR I from Takara Mirus Bio
Mouse Anti-Human Thyroid Hormone Rec., alpha1 / alpha2-Isotype Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit anti-QKI AbVantage Pack Polyclonal Antibody, Unconjugated from Bethyl Laboratories
Biology Products: